Bionano Genomics Announces the Final Speaker Lineup for 2022 Symposium
– 27 different customers representing
– 31 oral presentations across four consecutive days
– Topics span the application of OGM in genetic disease and cancer research
– 45% of presentations are from
“We believe Symposium is the quintessential event for the OGM community to come together and share the progress they are making and their ideas for expanding the utility of OGM,” said
“Symposium in 2021 marked a historic event where OGM users showcased their data. Since then, we have made significant improvements in OGM workflow and data analysis which have allowed our customers around the world to advance their clinical and translational research. We have seen the implementation of our Saphyr system across a broad range of clinical research applications for consolidating traditional cytogenetics workflows to OGM as well as demonstrating its utility in combination with NGS,” said
Each session of Symposium will start at
Speaker |
Institution | State / Country | Talk Title |
Validation of Optical Genome Mapping for Preimplantation Genetic Analysis – Structural Rearrangement (PGD-SR) Applications | |||
Dr. |
Assistance Publique–Hôpitaux de |
Balanced Translocations Associated with Male Infertility: How Optical Genome Mapping Could Lead to New Discoveries? | |
Dr. |
Clinical Utility of Optical Genome Mapping in a |
||
Dr. Alexander Hoischen | Nijmegen, |
Optical Genome Mapping: Mapping Difficult Structural Variant Types - Repeat Expansions | |
Dr. |
Validation Study of Optical Genome Mapping for Postnatal and Prenatal Clinical Research According to Established NYSDOH Guidelines | ||
Dr. |
Enhanced Structural Variation Detection with OGM in Constitutional Disorders | ||
Speaker |
Institution | State / Country | Talk Title |
Characterization of Plasma Cell Dyscrasias (PCD) by Optical Genome Mapping | |||
Dr. |
The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia | ||
Dr. |
Hospital |
The |
|
Dr. |
University Hospitals Leuven | Leuven, |
Opportunities of Optical Genome Mapping for Genetic Diagnosis in Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia |
Dr. |
Nijmegen, |
Technical and Clinical Validation of Optical Genome Mapping | |
Dr. |
Hospital Infantil Universitario Niño Jesús | Optical Genome Mapping for Diagnosis of Paediatric Leukaemia | |
Dr. |
Assessing Genomic Aberrations in AML using Optical Genome Mapping: Insights from a National Multi-Center Study | ||
Dr. |
Harvard Medical School Brigham and |
Shining a New Light on Cancer Cytogenetics: Leveraging Novel Technological Approaches for Improved Understanding in B-ALL | |
Dr. |
Laboratory Medicine Program, |
A Year in Review: Parallel Testing of Hematologic Malignancies Using Optical Genome Mapping Compared to Conventional Cytogenetics | |
Dr. |
Quest Diagnostics | Optical genome mapping: Utility for stratification of B-CLL by accurate identification of clinically relevant structural variants | |
Speaker |
Institution | Talk Title | |
Dr. |
Hospital Infantil Universitario Niño Jesús | Optical Genome Mapping: Application for Analysis of Non-Haematological Cancers | |
Dr. |
Oulu, |
Optical Genome Mapping in Unexplained High-Risk Breast Cancer Families | |
Dr. |
Vigor and Reproducibility in Research: The Cell |
||
Dr. |
The Chromosomal Landscape of Mesothelioma | ||
Dr. |
Instituto de Biomedicina de |
Complex Rearrangement Patterns in Undifferentiated Small Round Cell Sarcomas Associated with Poor Outcomes in Clinical Research | |
Dr. |
Utility of Optical Genome Mapping for the Chromosomal Characterization of Solid Tumors | ||
Speaker |
Institution | Talk Title | |
Dr. |
Nijmegen, |
Optical Genome Mapping: Different Types of Hidden SV's in Families with Inherited Retinal Diseases | |
Dr. |
Princess Máxima |
Enlightening the Dark Matter of the Genome: OGM Identifies a Germline Retrotransposon Insertion in SMARCB1 in Two Siblings with Atypical Teratoid Rhabdoid Tumors | |
Dr. |
Children's Hospital Los Angeles | OGM and Capture-Based RNA-Seq Enable Comprehensive Genomic Characterization of Pediatric B-lymphoblastic Leukemias | |
bit.bio | Cytogenetic QC at bit.bio: How a Next-Generation Cytogenetics Platform Enhances Quality Control of Next-Generation Cells | ||
Dr. Saumyaa Saumyaa | AstraZeneca | Detection and Characterization of On- and Off-target Integration of Foreign DNA in the Host Genomes, for Therapeutic Cell and |
|
Dr. |
Assistance Publique–Hôpitaux de |
Molecular Characterization of Genome Structural Variants in Developmental Disorders: Comparison Between OGM and Short Read WGS | |
Dr. |
Combined NGS and OGM Reveal the Complex Structures of Circular Extrachromosomal DNA and other Focal Amplifications in Cancer Genomes | ||
Dr. |
Clinical Utility of Combined Optical Genome Mapping and Comprehensive Genomic Sequencing in Robust Evaluation of Hematological Cancers | ||
Dr. |
A Comprehensive Assessment of a Large MDS Cohort at MD Anderson Cancer Center Using Optical Genome Mapping and a |
Symposium registration is open to all and there is no charge for attending this event. Register today at https://www.labroots.com/ms/virtual-event/bngo2022
About
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the anticipated benefits of the Symposium, our plans to conduct a Symposium in
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
+1 (858) 366-3243
amy@juniper-point.com
Media Relations:
Seismic
+1 (503) 799-7520
michael@teamseismic.com
Source: Bionano Genomics